Pottayil G. Sasikumar

Statistics

Publications

Citations

460

H-Index

Active since

2002

Affiliations

Aurigene Discovery Technologies (India)(Current)

Washington University in St. Louis

National Cancer Institute

Biota Pharmaceuticals (United States)

University of Washington

Pottayil G. Sasikumar is an author at Aurigene Discovery Technologies (India) specializing in immunotherapy, cancer immunotherapy, and immune checkpoint inhibitors.

ORCID

Publications per year

2002–2021

Publications

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi et al. · Communications Biology · 2021 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17

Anti-PD-L1 peptide improves survival in sepsis

Yuichiro Shindo, Jacquelyn S. McDonough, Katherine Chang et al. · Journal of Surgical Research · 2016 · 110 citations · Full text

Veterinary Medicine, Clinical Sciences, Immunology +10

A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Pottayil G. Sasikumar, Raghuveer Ramachandra, Srinivas Adurthi et al. · Molecular Cancer Therapeutics · 2019 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events

Pottayil G. Sasikumar, Rajeev Shrimali, Sreenivas Adurthi et al. · Journal for ImmunoTherapy of Cancer · 2013 · 19 citations · Full text

Medicine, Pharmacology, Cancer Pharmacology +13

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Casey R. Ager, Matthew J. Reilley, Courtney Nicholas et al. · Journal for ImmunoTherapy of Cancer · 2016 · 17 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 13